The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The phase 3 inMIND trial evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide in adult patients with relapsed or refractory follicular lymphoma. The trial showed that the treatment reached its primary endpoint and that the treatment was well tolerated, with a manageable safety profile.
As experience with the lymphoma drug glofitamab shows, global oncology trials sometimes fall short on representation of US patients and ethnic diversity. Raising awareness among community oncologists and use of AI for trial matching could help.
In this session from the SOHO Insider Community Oncology Brown Bag series, Dr. Krish Patel provides an overview on building partnerships between community and academic centers. Host Dr. Loretta Nastoupil also discusses with Dr. Patel a few points including how to get started with a coordinator.
During a session at AACR 2026, NCI Director Anthony Letai, MD, PhD, said that despite a turbulent past year, the institute is stable and its mission unchanged.
Accord BioPharma, the therapy’s manufacturer, expects a permanent Q-code from the US Centers for Medicare & Medicaid Services.
To access the SOHO Career Center click the following link.
